GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Earnings per Share (Diluted)

Gland Pharma (NSE:GLAND) Earnings per Share (Diluted) : ₹46.89 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Earnings per Share (Diluted)?

Gland Pharma's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ₹11.68. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹46.89.

Gland Pharma's EPS (Basic) for the three months ended in Mar. 2024 was ₹11.68. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹46.90.

Gland Pharma's EPS without NRI for the three months ended in Mar. 2024 was ₹11.68. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ₹46.89.

During the past 12 months, Gland Pharma's average EPS without NRIGrowth Rate was -6.20% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -9.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.70% per year.

During the past 7 years, Gland Pharma's highest 3-Year average EPS without NRI Growth Rate was 47.30% per year. The lowest was -9.40% per year. And the median was 20.10% per year.


Gland Pharma Earnings per Share (Diluted) Historical Data

The historical data trend for Gland Pharma's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Earnings per Share (Diluted) Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Earnings per Share (Diluted)
Get a 7-Day Free Trial 47.33 62.99 73.64 47.43 46.89

Gland Pharma Quarterly Data
Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.77 11.78 11.78 11.65 11.68

Competitive Comparison of Gland Pharma's Earnings per Share (Diluted)

For the Drug Manufacturers - General subindustry, Gland Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gland Pharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Gland Pharma's PE Ratio falls into.



Gland Pharma Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Gland Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(7724.6-0)/164.739
=46.89

Gland Pharma's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(1924.2-0)/164.743
=11.68

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹46.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Gland Pharma  (NSE:GLAND) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Gland Pharma Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Gland Pharma (NSE:GLAND) Business Description

Traded in Other Exchanges
Address
Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines